Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism

Nafee, Tarek; Gibson, C. Michael; Yee, Megan K.; Alkhalfan, Fahad; Chi, Gerald; Travis, Ryan; Mir, Mahshid; Kalaycı, Arzu; Jafarizade, Mehrian; Ganti, Aditya; Kazmi, Syed Hassan A.; Ghaffarpasand, Eiman; Pitliya, Anmol; Datta, Sudarshana; Sharfaei, Sadaf; Alihashemi, Mahda; Elsaiey, Ahmed; Qamar, Iqra; Jahansouz, Mohamadmostafa; Talib, Usama; Kahe, Farima; Habibi, Shaghayegh; Abdelwahed, Mohammed; Tariq, Feham; Kaur, Manpreet; Younes, A.; Walia, Sargun Singh; Singh, Amandeep; Dildar, Syed Muhammad; Afzal, M.; Kernéis, Mathieu

doi:10.1080/14779072.2018.1534068

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, to address some of the challenges associated with cell therapeutic approaches, embedding cells into 3D biodegradable scaffolds may better preserve cell survival and enhance cell engraftment after transplantation, consequently improving cardiac cell therapy compared with direct intramyocardial injection of isolated cells. 16,17 Transplantation of a tissue-engineered heart (e.g., cardiac tissue patches, hydrogel, or hybrid composites functionalized with CMs) could enhance therapeutic effects by an increased engraftment rate, which in turn, results in the prolonged release of healthy cytokines, reduction in left ventricular (LV) dilation, and LV wall stresses. Another advantage of this regenerative approach is that the bioengineering of heart muscle can be achieved ex vivo, under precise and controllable conditions, for later implantation.…”

Section: Nanoengineered Electroconductive Biomaterials 121mentioning

confidence: 99%

Electroconductive Nanobiomaterials for Tissue Engineering and Regenerative Medicine

et al. 2020

View full text Add to dashboard Cite

Regenerative medicine aims to engineer tissue constructs that can recapitulate the functional and structural properties of native organs. Most novel regenerative therapies are based on the recreation of a three-dimensional environment that can provide essential guidance for cell organization, survival, and function, which leads to adequate tissue growth. The primary motivation in the use of conductive nanomaterials in tissue engineering has been to develop biomimetic scaffolds to recapitulate the electrical properties of the natural extracellular matrix, something often overlooked in numerous tissue engineering materials to date. In this review article, we focus on the use of electroconductive nanobiomaterials for different biomedical applications, particularly, very recent advancements for cardiovascular, neural, bone, and muscle tissue regeneration. Moreover, this review highlights how electroconductive nanobiomaterials can facilitate cell to cell crosstalk (i.e., for cell growth, migration, proliferation, and differentiation) in different tissues. Thoughts on what the field needs for future growth are also provided.

show abstract

Section: Nanoengineered Electroconductive Biomaterials 121mentioning

confidence: 99%

Electroconductive Nanobiomaterials for Tissue Engineering and Regenerative Medicine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…17 The newest factor Xa inhibitor, betrixaban, is currently only approved for extended prophylaxis against VTE in acutely ill patients. 18,19 All factor Xa inhibitors have quick onset of action. Rivaroxaban reaches peak plasma concentration 2 to 4 hours after ingestion, apixaban in 1 to 3 hours, edoxaban in 1 to 1.5 hours, and betrixaban in 3 to 4 hours.…”

Section: Direct Thrombin Inhibitorsmentioning

confidence: 99%

“…17 The newest factor Xa inhibitor, betrixaban, is currently only approved for extended prophylaxis against VTE in acutely ill patients. 18,19…”

Section: Pharmacology and Indicationsmentioning

confidence: 99%

Periprocedural Anticoagulation Management For Nonoperating Room Anesthesia Procedures: A Clinical Guide

Tao

Oprea

2019

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

Non-operating room anesthesia presents unique challenges for anesthesiologists. Limited preprocedural optimization and unfamiliarity with the location and procedure itself add to the difficulties in delivering safe care for these patients. Management of chronic oral anticoagulation can prove especially problematic since risks of bleeding for non-operating room procedures vary widely and differ from traditional surgeries. In addition, many physicians may not be familiar with the growing number of newly approved oral anticoagulants and their periprocedural management. This review will examine common non-operating procedures, their risks of bleeding, as well as pharmacokinetics of oral anticoagulants available on the market and periprocedural management options.

show abstract

Coagulation and Anticoagulants

Goubran

Bosch

Stakiw

2019

Precision Anticoagulation Medicine

View full text Add to dashboard Cite

Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism

Cited by 5 publications

References 28 publications

Electroconductive Nanobiomaterials for Tissue Engineering and Regenerative Medicine

Electroconductive Nanobiomaterials for Tissue Engineering and Regenerative Medicine

Periprocedural Anticoagulation Management For Nonoperating Room Anesthesia Procedures: A Clinical Guide

Coagulation and Anticoagulants

Contact Info

Product

Resources

About